The US company's lead program is focused on novel forms of glucose responsive insulins that will eliminate the need for both basal and prandial insulins through a single weekly dose.

In May 2018, AmideBio announced the appointment of Eli Lilly's Pawel Fludzinski as chief executive, at a time when the company is developing a number of drug candidates and talking with potential collaborators and investors.